UY36851A - Compuestos para uso en aplicaciones antibacterianas - Google Patents

Compuestos para uso en aplicaciones antibacterianas

Info

Publication number
UY36851A
UY36851A UY0001036851A UY36851A UY36851A UY 36851 A UY36851 A UY 36851A UY 0001036851 A UY0001036851 A UY 0001036851A UY 36851 A UY36851 A UY 36851A UY 36851 A UY36851 A UY 36851A
Authority
UY
Uruguay
Prior art keywords
compounds
antibacterial applications
antibacterial
applications
antibacterials
Prior art date
Application number
UY0001036851A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Hennessy Alan
Haifeng Cui
Qi Jin
James Miles Timothy
Frederick Moss Stephen
David Pearson Neil
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY36851A publication Critical patent/UY36851A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
UY0001036851A 2015-08-16 2016-08-12 Compuestos para uso en aplicaciones antibacterianas UY36851A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562205732P 2015-08-16 2015-08-16
US201662308928P 2016-03-16 2016-03-16

Publications (1)

Publication Number Publication Date
UY36851A true UY36851A (es) 2017-03-31

Family

ID=57218948

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036851A UY36851A (es) 2015-08-16 2016-08-12 Compuestos para uso en aplicaciones antibacterianas

Country Status (22)

Country Link
US (2) US10364254B2 (OSRAM)
EP (1) EP3334739A2 (OSRAM)
JP (1) JP6757402B2 (OSRAM)
KR (1) KR20180038046A (OSRAM)
CN (1) CN108137616B (OSRAM)
AU (2) AU2016307969C1 (OSRAM)
CA (1) CA2995715A1 (OSRAM)
CL (1) CL2018000403A1 (OSRAM)
CO (1) CO2018002204A2 (OSRAM)
CR (1) CR20180111A (OSRAM)
DO (1) DOP2018000049A (OSRAM)
EA (1) EA033314B1 (OSRAM)
HK (1) HK1248680A1 (OSRAM)
IL (1) IL257265B (OSRAM)
MA (1) MA42621A (OSRAM)
MX (1) MX2018002033A (OSRAM)
PE (1) PE20181143A1 (OSRAM)
PH (1) PH12018500358A1 (OSRAM)
TW (1) TW201722965A (OSRAM)
UY (1) UY36851A (OSRAM)
WO (1) WO2017029602A2 (OSRAM)
ZA (1) ZA201800722B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
WO2019180634A1 (en) 2018-03-23 2019-09-26 Glaxosmithkline Intellectual Property Development Limited Synthesis of oxazinone-containing bicyclic aromatic and heteroaromatic aldehydes
WO2021009212A1 (en) 2019-07-16 2021-01-21 Idorsia Pharmaceuticals Ltd Antibacterial quinolone derivatives
CN111269247B (zh) * 2020-03-04 2020-11-24 河南科技大学第一附属医院 具有抑制大肠杆菌作用的噻嗪酮药物分子的制备方法
JP2025510646A (ja) 2022-03-14 2025-04-15 スラップ ファーマシューティカルズ エルエルシー 多環式化合物
WO2025132870A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Intellectual Property (No.4) Limited Chemical compounds and uses thereof

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (OSRAM) * 1969-10-13 1971-09-23 Eisai Co Ltd
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AT396872B (de) 1985-07-30 1993-12-27 Glaxo Group Ltd Gerät zur verabreichung von medikamenten in pulverform
JPH0733379B2 (ja) * 1986-06-27 1995-04-12 エーザイ株式会社 光学活性α−トコフエロ−ルの製造方法
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
DE60025048D1 (de) 2000-07-21 2006-01-26 Ljudmila Petrovna Maljuk Teller für stehempfänge
DE60125373T2 (de) 2000-07-26 2007-10-18 Smithkline Beecham P.L.C., Brentford Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
AU2002219175A1 (en) 2000-12-21 2002-07-01 Ciba Speciality Chemicals Holding Inc. Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
WO2003064421A1 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine derivatives
AU2003239302A1 (en) 2002-01-29 2003-09-02 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
AR040335A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
AU2003279690A1 (en) 2002-06-27 2004-01-19 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
WO2004035569A2 (de) 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
JP4704755B2 (ja) 2002-11-05 2011-06-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
JP4654035B2 (ja) 2002-11-05 2011-03-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200507841A (en) * 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
KR101281775B1 (ko) 2003-12-19 2013-07-15 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 소프트 또는 임프린트 리소그래피를 이용하여 분리된마이크로- 및 나노- 구조를 제작하는 방법
WO2007021762A2 (en) 2005-08-09 2007-02-22 The University Of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US7691850B2 (en) 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1773831A1 (en) 2004-07-08 2007-04-18 Glaxo Group Limited Antibacterial agents
WO2006010040A2 (en) 2004-07-09 2006-01-26 Glaxo Group Limited Antibacterial agents
EP1773343A4 (en) 2004-07-13 2009-05-13 Glaxo Group Ltd ANTIBACTERIAL AGENTS
JP2008507543A (ja) 2004-07-22 2008-03-13 グラクソ　グループ　リミテッド 抗細菌剤
ATE484509T1 (de) 2004-08-02 2010-10-15 Glaxo Group Ltd Antibakterielle mittel
US20070161627A1 (en) 2004-08-09 2007-07-12 Miller William H Antibacterial agents
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP4887297B2 (ja) 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
ATE466857T1 (de) 2004-10-05 2010-05-15 Actelion Pharmaceuticals Ltd Neue piperidin-antibiotika
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
JP2008528598A (ja) * 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008542249A (ja) * 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ 抗細菌活性を持つアミノピペリジンキノリン及びそのアザ等立体類似体
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2006137485A1 (ja) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
US8944804B2 (en) 2006-01-04 2015-02-03 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
EP1987040B1 (en) * 2006-02-15 2010-11-10 Actelion Pharmaceuticals Ltd. Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
KR101409261B1 (ko) 2006-05-26 2014-06-18 다이쇼 세이야꾸 가부시끼가이샤 신규의 복소환 화합물 또는 그 염 및 그 중간체
EP1992628A1 (en) * 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
WO2008013952A2 (en) 2006-07-27 2008-01-31 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
CL2007003693A1 (es) * 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
GB0707704D0 (en) * 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
WO2009024342A2 (en) * 2007-08-23 2009-02-26 Syngenta Participations Ag Novel microbiocides
CN101896337B (zh) 2007-10-12 2013-10-30 流体科技公司 用于生产颗粒和图案化膜的系统和方法
JP5620636B2 (ja) 2007-11-26 2014-11-05 富山化学工業株式会社 新規な複素環化合物またはその塩を含有する抗菌剤
MY158520A (en) * 2008-10-07 2016-10-14 Actelion Pharmaceuticals Ltd Tricyclic oxazolidinone antibiotic compounds
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
TW201022279A (en) * 2008-11-14 2010-06-16 Astrazeneca Ab Chemical compounds
KR101690643B1 (ko) 2008-12-05 2016-12-28 리퀴디아 테크놀로지스 인코포레이티드 패턴 재료 제조 방법
CN102232078B (zh) * 2008-12-12 2014-07-16 埃科特莱茵药品有限公司 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物
WO2011008737A2 (en) 2009-07-13 2011-01-20 The University Of North Carolina At Chapel Hill Engineered aerosol particles, and associated methods
TW201209056A (en) * 2010-05-25 2012-03-01 Taisho Pharmaceutical Co Ltd Novel heterocyclic compound or salt thereof
WO2013003383A1 (en) * 2011-06-27 2013-01-03 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
CA2854266A1 (en) * 2011-11-30 2013-06-06 Actelion Pharmaceuticals Ltd 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
MX362338B (es) 2013-04-16 2019-01-11 Idorsia Pharmaceuticals Ltd Derivados biaromaticos antibacterianos.
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas

Also Published As

Publication number Publication date
CO2018002204A2 (es) 2018-06-20
MX2018002033A (es) 2018-06-15
US20190270755A1 (en) 2019-09-05
DOP2018000049A (es) 2018-03-30
US10683307B2 (en) 2020-06-16
CN108137616B (zh) 2020-06-26
WO2017029602A2 (en) 2017-02-23
AU2019200226B2 (en) 2020-01-23
AU2016307969C1 (en) 2019-09-05
MA42621A (fr) 2018-06-20
US20190031680A1 (en) 2019-01-31
AU2016307969B2 (en) 2019-02-14
IL257265A (en) 2018-03-29
PE20181143A1 (es) 2018-07-17
CL2018000403A1 (es) 2018-07-06
CN108137616A (zh) 2018-06-08
US10364254B2 (en) 2019-07-30
EP3334739A2 (en) 2018-06-20
JP6757402B2 (ja) 2020-09-16
HK1248680A1 (zh) 2018-10-19
EA033314B1 (ru) 2019-09-30
AU2019200226A1 (en) 2019-01-31
JP2018523675A (ja) 2018-08-23
CA2995715A1 (en) 2017-02-23
ZA201800722B (en) 2019-07-31
AU2016307969A1 (en) 2018-03-08
WO2017029602A3 (en) 2017-04-13
PH12018500358A1 (en) 2018-09-03
TW201722965A (zh) 2017-07-01
CR20180111A (es) 2018-04-12
EA201890412A1 (ru) 2018-08-31
KR20180038046A (ko) 2018-04-13
IL257265B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
CO2017011851A2 (es) Compuestos novedosos
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
MX386584B (es) Composiciones de liberación retardada de linaclotida.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
MX2015009479A (es) Compuestos y metodos para tratar infecciones bacterianas.
CL2015000608A1 (es) Formulaciones de daptomicina y usos de la misma
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221121